Comments on Initial experience with teriparatide in the United States

被引：11

作者：

Harper, Kristine D. ^{[1
]}

Krege, John H. ^{[1
]}

Marcus, Robert ^{[1
]}

Mitlak, Bruce H. ^{[1
]}

机构：

[1] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA

来源：

CURRENT MEDICAL RESEARCH AND OPINION | 2006年 / 22卷 / 10期

关键词：

D O I：

10.1185/030079906X132578

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1927 / 1927

页数：1

共 6 条

[1]

[Anonymous], 2019, SEER STAT SOFTWARE

[2] Initial experience with teriparatide in the United States [J].

Gold, Deborah T. ;

Pantos, Barbara S. ;

Masica, Daniel N. ;

Misurski, Derek A. ;

Marcus, Robert .

CURRENT MEDICAL RESEARCH AND OPINION, 2006, 22 (04) :703-708

[3]

Tashjian AH, 2006, J BONE MINER RES, V21, P354, DOI 10.1359/JBMR.051023

[4] Commentary on clinical safety of recombinant human parathyroid hormone 1-34 in the treatment of osteoporosis in men and postmenopausal women [J].

Tashjian, AH ;

Chabner, BA .

JOURNAL OF BONE AND MINERAL RESEARCH, 2002, 17 (07) :1151-1161

[5] Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety [J].

Vahle, JL ;

Sato, M ;

Long, GG ;

Young, JK ;

Francis, PC ;

Engelhardt, JA ;

Westmore, MS ;

Ma, YFL ;

Nold, JB .

TOXICOLOGIC PATHOLOGY, 2002, 30 (03) :312-321

[6] Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose [J].

Vahle, JL ;

Long, GG ;

Sandusky, G ;

Westmore, M ;

Ma, YL ;

Sato, M .

TOXICOLOGIC PATHOLOGY, 2004, 32 (04) :426-438

← 1 →